At a glance
- Originator Sanofi-Synthelabo
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 31 Dec 1996 No-Development-Reported for Bacterial infections in France (Parenteral)